Markets ended flat on Thursday after a volatile session, with analysts maintaining a positive outlook and recommending a buy-on-dips strate...

Equity markets experienced pressure on monthly expiry day, slipping nearly half a percent. Shares of Tata Investment, Narayana Hrudalaya, H...

Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540...

Drug maker Alembic Pharma on Monday reported Rs 180 crore net profit in Q3FY24, which is a 48% year-on-year (YoY) increase compared to the ...

Revenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amorti...

Flash floods in the Teesta River has led to disruption in operations at its Sikkim-based manufacturing plant, said Alembic Pharmaceuticals ...

The Vadodara-based company said consolidated profit rose to 1.21 billion rupees ($14.6 million) for the quarter ended June 30 from a loss o...

Alembic Pharma is looking forward to high growth with API and RoW businesses reporting decent growth. Besides, new products in pipeline and...

Alembic Global Holdings SA has received tentative approval from the US Food and Drug Administration for its abbreviated new drug applicatio...

The company had posted a net profit of Rs 124 crore for the corresponding period of the previous fiscal.

Revenue from operations stood at Rs 1,018.15 crore in the reported quarter as against Rs 840.02 crore.

International formulations sales grew to Rs 587 crore from Rs 262 crore in the year-ago period, the company said.

Investment in R&D and new facilities focus on exports, new launches and likely growth in revenue of about 35% in the coming years has made ...

After remaining on the sidelines for a decade, Alembic Pharma’s stock has been in the limelight in the recent past.

100-year-old Vadodara-based firm, Alembic Pharmaceuticals is the second-best pharma stock in the BSE 500 in the past one year.

Alembic Pharmaceuticals posts 12% rise in Q2 net profit. Will add more to the basket of specialty products for growth.

Alembic Pharmaceuticals has posted 34% rise in net sales in its first quarter result after being carved out of Alembic Ltd.